Limited-Stage SCLC Management



Naiyer A. Rizvi, MD: Let’s talk a little bit next about limited-stage small cell lung cancer. Maybe, Ticiana, you can lead us through your kind of thinking for limited-stage patients.

Ticiana Leal, MD: When we have these patients in the clinic, we’ve talked about how about 20% of the patients with small call present with limited-stage disease. And I think it’s very important to do adequate staging. Routinely we’ll perform imaging of chest and liver adrenals, but PET-CT [positron emission tomography—computed tomography] as well as brain MRI [magnetic resonance imaging] to do full staging. And then have multidisciplinary evaluation. Our standard at the University of Wisconsin is based on the data regarding combinations of chemotherapy with cisplatin and etoposide. In this setting we really favor using the platinum with cisplatin. And then the radiation is where I think the data can somewhat fluctuate. We frequently still use the bid twice-a-day regimen, the Andrew T. Turrisi regimen. But we also acknowledge that it would be appropriate to use in certain settings the more prolonged course, which might be a situation that for a select number of patients may work better.

Transcript Edited for Clarity

Related Videos
Ashish Saxena, MD, PhD
Eric Vallieres, MD, FRCSC
Benjamin Levy, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD